OATD-02
Based on 1 publication(s) in Google Scholar
OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2146132-73-0
- 화학식: C12H25BN2O4
- 분자량:272.15
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) OATD-02
More
Biological Activity
제품 설명
IC50 & Target
20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), 28 nM (rARG1)
In Vitro
OATD-02 inhibits mouse ARG in BMDM cells with IC50 values of 912.9 nM and human ARG2 in transfected CHO-K1 cells with IC50 of 171.6 nM, and inhibits hARG1 in human primary hepatocytes at a much higher micromolar concentration (IC50 = 13 μM) [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
OATD-02 (5 mg/kg, oral gavage) increases fourfold of the L-arginine concentration in plasma sustained even 1 week after end of a treatment[1].
OATD-02 (twice per day at 50 mg/kg, oral gavage) inhibits the tumor growth in B16F10 orthotopic xenograft tumor model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B16F10 orthotopic xenograft tumor model[1]
-
Dosage:Twice per day at 50 mg/kg for 15days
-
Administration:Oral gavage
-
Result:Inhibited tumor growth (TGI 46%).
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2146132-73-0
-
분자량 272.15
-
화학식 C12H25BN2O4
-
SMILES
N[C@]1(C(O)=O)C[C@H](CCB(O)O)CC[C@H]1CN(C)C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-β/PD-L1 Bispecific Antibody. [Abstract]2024 Nov;11(43):e2408598. PMID: 39303165
순도&문서
-
Data Sheet (273 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
OATD-02 Related Classifications
HY-155108 Related Classifications
Powered by Bioz